// App-Quantinova.ai

CT289 : Phase 3, randomized, open-label LEAP-008 trial

Researchers

Presenter

  • Natasha B. Leighl

Principal Investigators

  • Rina Hui

  • Delvys Rodrguez-Abreu

  • Makoto Nishio

  • Matthew D. Hellmann

  • Chooi Lee

  • Xuan Deng

  • Debra Kush

  • Hossein Borghaei

  • Justin Gainor

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Westmead Hospital and University of Sydney, Sydney, Australia

  • Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas De Gran Canaria, Spain

  • Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research, Tokyo, Japan

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Eisai, Hatfield, Hertfordshire, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ

  • Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • Canada

  • Australia

  • Spain

  • Japan

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Lung Cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT02501096

  • NCT03976375

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved